Clinical Trials Advisory Committee
The primary purpose of the CTAC is to advise the Oversight Committee on important issues of the clinical trials. The CTAC shall give their expert opinion on the impact of current CPRIT mechanisms supporting clinical trials; give advice on opportunities to increase CPRIT’s impact on translating basic discoveries to clinical trials; and advise on mechanisms that would address barriers to patient enrollment in therapeutic clinical trials.
Members:
S. Gail Eckhardt, M.D., FASCO, Chair
|
Carlos L. Arteaga, M.D.
|
David S. Hong M.D.
|
Ronan J. Kelly M.D., MBA
|
Ruben A. Mesa, M.D., FACP
|
C. Kent Osborne, M.D.
|
C Patrick Reynolds, M.D., Ph.D.
|